137 related articles for article (PubMed ID: 38437485)
1. The Next Chapter of Renal Denervation After US Food and Drug Administration Approval.
Vongpatanasin W; Addo T
Circulation; 2024 Mar; 149(10):760-763. PubMed ID: 38437485
[No Abstract] [Full Text] [Related]
2. Overview of the 2018 US Food and Drug Administration Circulatory System Devices Panel Meeting on Device-Based Therapies for hypertension.
Khalid N; Rogers T; Shlofmitz E; Chen Y; Dan K; Torguson R; Weintraub WS; Waksman R
Cardiovasc Revasc Med; 2019 Oct; 20(10):891-896. PubMed ID: 31447315
[No Abstract] [Full Text] [Related]
3. Overview of the 2023 FDA Circulatory System Devices Advisory Panel Meeting on the Symplicity Spyral Renal Denervation System.
Chitturi KR; Haberman D; Wermers JP; Waksman R
Am Heart J; 2024 Mar; 269():108-117. PubMed ID: 38128897
[TBL] [Abstract][Full Text] [Related]
4. [Renal denervation in hypertension - pro].
Mahfoud F
Dtsch Med Wochenschr; 2012 Apr; 137(14):720. PubMed ID: 22454201
[No Abstract] [Full Text] [Related]
5. [Renal denervation in hypertension - contra].
Holzgreve H
Dtsch Med Wochenschr; 2012 Apr; 137(14):721. PubMed ID: 22454202
[No Abstract] [Full Text] [Related]
6. Pediatric contrast-enhanced ultrasound: shedding light on the pursuit of approval in the United States.
Darge K; Back SJ; Bulas DI; Feinstein SB; Ntoulia A; Volberg FM; Wilson SR; McCarville MB
Pediatr Radiol; 2021 Nov; 51(12):2128-2138. PubMed ID: 34117520
[TBL] [Abstract][Full Text] [Related]
7. Recent issues in breast cancer detection and the premarket approval by the Food and Drug Administration of a US system for breast lesion evaluation: what happened to science?
Kopans DB
Radiology; 1997 Feb; 202(2):315-6. PubMed ID: 9015048
[No Abstract] [Full Text] [Related]
8. Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval.
Parikh RB; Hubbard RA; Wang E; Royce TJ; Cohen AB; Clark AS; Mamtani R
JAMA Oncol; 2023 Apr; 9(4):567-569. PubMed ID: 36821118
[TBL] [Abstract][Full Text] [Related]
9. US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018.
Skydel JJ; Zhang AD; Dhruva SS; Ross JS; Wallach JD
Clin Trials; 2021 Aug; 18(4):488-499. PubMed ID: 33863236
[TBL] [Abstract][Full Text] [Related]
10. United States Food and Drug Administration Regulation of Human Cells, Tissues, and Gene Therapies.
Sanduja S; Lessey-Morillon L; Allen R; Wang X; Imperato G; Arcidiacono J
Adv Exp Med Biol; 2023; 1430():71-89. PubMed ID: 37526843
[TBL] [Abstract][Full Text] [Related]
11. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
12. Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US.
Ermer T; Canavan ME; Maduka RC; Li AX; Salazar MC; Kaminski MF; Pichert MD; Zhan PL; Mase V; Kluger H; Boffa DJ
JAMA Netw Open; 2022 Jun; 5(6):e2219535. PubMed ID: 35771575
[TBL] [Abstract][Full Text] [Related]
13. The US Food and Drug Administration Premarket Approval Process and the 515 Program Initiative: View From a Panel Chair.
Page RL
JAMA Cardiol; 2016 May; 1(2):119-20. PubMed ID: 27437880
[No Abstract] [Full Text] [Related]
14. Executive summary of the joint position paper on renal denervation of the Cardiovascular and Interventional Radiological Society of Europe and the European Society of Hypertension.
Moss JG; Belli AM; Coca A; Lee M; Mancia G; Peregrin JH; Redon J; Reekers JA; Tsioufis C; Vorwerk D; Schmieder RE
J Hypertens; 2016 Dec; 34(12):2303-2304. PubMed ID: 27755387
[TBL] [Abstract][Full Text] [Related]
15. The US Food and Drug Administration's Approval of Adjuvant Sunitinib for Renal Cell Cancer: A Case of Regulatory Capture?
Gyawali B; Goldstein DA
JAMA Oncol; 2018 May; 4(5):623-624. PubMed ID: 29522146
[No Abstract] [Full Text] [Related]
16. The US Food and Drug Administration Cardiorenal Advisory Panel and the drug approval process.
Roden DM; Temple R
Circulation; 2005 Apr; 111(13):1697-702. PubMed ID: 15811869
[No Abstract] [Full Text] [Related]
17. Cardiovascular Safety Communications After US Food and Drug Administration Approval of Contemporary Cancer Therapies.
Bonsu JM; Kola-Kehinde O; Kim L; Ruz P; Campbell CM; Brammer JE; Addison D
JAMA Oncol; 2021 Nov; 7(11):1722-1723. PubMed ID: 34591072
[TBL] [Abstract][Full Text] [Related]
18. Estimated Medicare Spending on Cancer Drug Indications With a Confirmed Lack of Clinical Benefit After US Food and Drug Administration Accelerated Approval.
Shahzad M; Naci H; Wagner AK
JAMA Intern Med; 2021 Dec; 181(12):1673-1675. PubMed ID: 34661616
[TBL] [Abstract][Full Text] [Related]
19. US Food and Drug Administration Approval of Drugs Not Meeting Pivotal Trial Primary End Points, 2018-2021.
Johnston JL; Ross JS; Ramachandran R
JAMA Intern Med; 2023 Apr; 183(4):376-380. PubMed ID: 36780148
[TBL] [Abstract][Full Text] [Related]
20. New drug application 21-628, Certican (everolimus), for the proposed indication of prophylaxis of rejection in heart transplantation: report from the Cardiovascular and Renal Drugs Advisory Committee, US Food and Drug Administration, November 16, 2005, Rockville, Md.
Hiatt WR; Nissen SE;
Circulation; 2006 Mar; 113(10):e394-5. PubMed ID: 16534016
[No Abstract] [Full Text] [Related]
[Next] [New Search]
